Viability of Breast Conservation Therapy Gives Patients ‘More of a Choice,’ Says Expert

Video

Judy C. Boughey, MD, of Mayo Clinic in Rochester, Minnesota indicated that breast conservation therapy, if it can be proven as a reasonable option for patients with multiple ipsilateral breast cancer, could offer patients more choice in treatment.

Demonstrating breast conservation surgery as a reasonable option for patients with multiple ipsilateral breast cancer may give women more of a choice in terms of treatment, according to Judy C. Boughey, MD.

During the 2022 San Antonio Breast Cancer Symposium (SABCS), CancerNetwork® spoke with Boughey, a surgical oncologist of the Division of Breast and Melanoma Surgical Oncology and the Department of Surgery at Mayo Clinic in Rochester, Minnesota, about the historical reasons why mastectomy is still used today and the potential impact of breast conservation therapy on local recurrence rates.

As such, Boughey and her colleagues aimed to assess the efficacy of breast conservation therapy as part of the phase 2 ACOSOG Z11102 (NCT01556243).

Transcript:

Women who have multiple ipsilateral breast cancer are often recommended for mastectomy. And this is based off the literature that historically showed a high rate of local recurrence in the breast; patients were treated with breast conservation if they had more than one foci of disease in the breast.

However, some more recent contemporary single institution studies have been reassuring and showing some lower local recurrence rates with the use of breast conserving surgery in patients with multiple ipsilateral breast cancer. We thought that this was an important question to ask for our patients in a prospective clinical trial.

We're seeing more and more patients who are being worked up for breast cancer and then being diagnosed with multiple foci of disease in the breast [due to] advances in screening, increased use of screening, and improvements in not only the screening modalities, but also diagnostic modalities, as well as the use of MRI.

With more use of MRI, you've got a higher likelihood of finding a second small foci elsewhere in the breast, [which] then at times commits the patient to require a mastectomy. If we could show that breast conservation surgery was a reasonable option for these women, then these women would have more of a choice.

Reference

Boughey JC, Rosenkranz KM, Ballman KV, et al. Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer – results from ACOSOG Z11102 (Alliance). Presented at the 2022 San Antonio Breast Cancer Symposium; December 6-10, 2022; San Antonio, TX; abstract GS4-01.

Recent Videos
Performance status, age, and comorbidities may impact benefit seen with immunotherapy vs chemotherapy in patients with breast cancer.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
An “avalanche of funding” has propelled the kidney cancer field forward, says Jason Muhitch, PhD.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Kidney cancer advocacy efforts have spread the urgency and importance of funding research in the field to members of Congress.
Advocacy efforts have yielded a dramatic increase in kidney cancer research, according to Elizabeth P. Henske, MD.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Related Content